Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Combination of the Hedgehog Pathway Inhibitor LDE225 and Nilotinib Eliminates Chronic Myeloid Leukemia Stem and Progenitor Cells.

David A Irvine, roMB, ChB, Bin Zhang, MD, PhD, Elaine K Allan, BSc, Tessa L Holyoake, PhD, MB, ChB, FRCP, FRCPath, FRSE, Marion Dorsch, PhD, Paul W Manley, PhD, Ravi Bhatia, MD, PhD, Mhairi Copland, PhD, BSc, MB, ChB, MRCP, FRCPath

Blood (2009) 114 (22): 1428.

https://doi.org/10.1182/blood.V114.22.1428.1428

Published: 2009

Journal Articles

BMS-214662 Eliminates CML Stem Cells and Is Active Against Blast Crisis CML and Cells Expressing BCR-ABL Kinase Mutations.

Mhairi Copland, MD, Linda Richmond, BSc, Ashley Hamilton, BSc, Elaine K. Allan, BSc, Junia V. Melo, MD, PhD, Tessa L. Holyoake, MD, PhD

Blood (2006) 108 (11): 739.

https://doi.org/10.1182/blood.V108.11.739.739

Published: 2006

Journal Articles

BMS-214662 Targets Quiescent Chronic Myeloid Leukaemia Stem Cells and Enhances the Activity of Both Imatinib and Dasatinib (BMS-354825).

Mhairi Copland, MD, Ashley Hamilton, BSc, Elaine K. Allan, BSc, Valerie Brunton, PhD, Tessa L. Holyoake, MD, PhD

Blood (2005) 106 (11): 693.

https://doi.org/10.1182/blood.V106.11.693.693

Published: 2005

Journal Articles

Dasatinib (BMS-354825) Has Increased Activity Against Bcr-Abl Compared to Imatinib in Primary CML Cells In Vitro , but Does Not Eradicate Quiescent CML Stem Cells.

Mhairi Copland, MD, Ashley Hamilton, BSc, Janet W. Baird, PhD, Martin Barow, PhD, Elaine K. Allan, BSc, Lucy J. Elrick, PhD, Tessa L. Holyoake, MD, PhD

Blood (2005) 106 (11): 695.

https://doi.org/10.1182/blood.V106.11.695.695

Published: 2005

Journal Articles

G-CSF as a Potent Mitogen Augments the Elimination of CML Stem Cells by Imatinib Mesylate In Vitro .

Heather G. Jorgensen, PhD MRPharmS, Mhairi Copland, MD, Elaine K. Allan, BSc(Hons), Allen C. Eaves, MD PhD, Connie J. Eaves, PhD, Xiaoyan Jiang, MD PhD, Tessa L. Holyoake, MD PhD

Blood (2004) 104 (11): 2941.

https://doi.org/10.1182/blood.V104.11.2941.2941

Published: 2004

Journal Articles

Enhanced Primary CML Stem Cell Elimination by Bryostatin Priming with Imatinib Mesylate In Vitro .

Heather G. Jorgensen, PhD, MRPharmS, Elaine K. Allan, BSc (Hons), Joanne C. Mountford, PhD, Linda Richmond, BSc(Hons), Moira A. Elliott, PhD, MRPharmS, Tessa L. Holyoake, MD, PhD

Blood (2004) 104 (11): 1997.

https://doi.org/10.1182/blood.V104.11.1997.1997

Published: 2004

NARROW

Combination of the Hedgehog Pathway Inhibitor LDE225 and Nilotinib Eliminates Chronic Myeloid Leukemia Stem and Progenitor Cells.

BMS-214662 Eliminates CML Stem Cells and Is Active Against Blast Crisis CML and Cells Expressing BCR-ABL Kinase Mutations.

BMS-214662 Targets Quiescent Chronic Myeloid Leukaemia Stem Cells and Enhances the Activity of Both Imatinib and Dasatinib (BMS-354825).

Dasatinib (BMS-354825) Has Increased Activity Against Bcr-Abl Compared to Imatinib in Primary CML Cells In Vitro , but Does Not Eradicate Quiescent CML Stem Cells.

G-CSF as a Potent Mitogen Augments the Elimination of CML Stem Cells by Imatinib Mesylate In Vitro .

Enhanced Primary CML Stem Cell Elimination by Bryostatin Priming with Imatinib Mesylate In Vitro .

Email alerts

ASH Publications

American Society of Hematology

Combination of the Hedgehog Pathway Inhibitor LDE225 and Nilotinib Eliminates Chronic Myeloid Leukemia Stem and Progenitor Cells.

BMS-214662 Eliminates CML Stem Cells and Is Active Against Blast Crisis CML and Cells Expressing BCR-ABL Kinase Mutations.

BMS-214662 Targets Quiescent Chronic Myeloid Leukaemia Stem Cells and Enhances the Activity of Both Imatinib and Dasatinib (BMS-354825).

Dasatinib (BMS-354825) Has Increased Activity Against Bcr-Abl Compared to Imatinib in Primary CML Cells In Vitro , but Does Not Eradicate Quiescent CML Stem Cells.

G-CSF as a Potent Mitogen Augments the Elimination of CML Stem Cells by Imatinib Mesylate In Vitro .

Enhanced Primary CML Stem Cell Elimination by Bryostatin Priming with Imatinib Mesylate In Vitro .

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only